Literature DB >> 10722237

Increased expression of tumor necrosis factor-alpha in diabetic macrovasculopathy.

N Clausell1, P Kalil, A Biolo, S Molossi, M Azevedo.   

Abstract

Large vessel disease, a common feature of diabetes mellitus, appears to run an aggressive course, but its cellular and molecular aspects remain partially elucidated. Although in common atherosclerosis and especially in other forms of accelerated vasculopathy, immunoinflammatory mechanisms participate in the disease process, it is unclear whether this is present in diabetic vasculopathy. We hypothesized that diabetic macrovasculopathy, compared with classical atherosclerosis, is associated with increased immunoinflammatory features and matrix accumulation. In this study, vessel segments obtained after lower-limb amputation for advanced atherosclerotic disease, from type 2 diabetic patients (n = 20; 68.9+/-10.9 years) and nondiabetic patients (n = 16; 67.1+/-14.6 years) were analyzed. Histological characteristics (extent of intimal proliferation, cellularity, and fibrosis) were semiquantitatively graded in the two lesion types. Using immunohistochemistry, the presence of T cells and macrophages, accumulation of fibronectin, and expression of tumor necrosis factor-alpha was also assessed. Histological features of these advanced atherosclerotic lesions were similar in the two lesions examined. By immunohistochemistry, a similar pattern of T-cell and macrophage infiltration and fibronectin accumulation was observed. Nevertheless, increased expression of tumor necrosis factor-alpha was observed in diabetic lesions (13/19 patients had positive staining), whereas only 2 of 16 lesions from nondiabetic patients had positive staining (p < 0.003), with an odds ratio of 15.17 (confidence interval 2.12-139.5). These data suggest that increased expression of tumor necrosis factor-alpha observed in the diabetic lesions may reflect an enhanced inflammatory activity associated with the development of vascular lesions in type 2 diabetic patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10722237     DOI: 10.1016/s1054-8807(98)00033-7

Source DB:  PubMed          Journal:  Cardiovasc Pathol        ISSN: 1054-8807            Impact factor:   2.185


  6 in total

Review 1.  Effects of diabetes on the eye.

Authors:  Gerard A Lutty
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-12-13       Impact factor: 4.799

2.  Aldose reductase regulates vascular smooth muscle cell proliferation by modulating G1/S phase transition of cell cycle.

Authors:  Ravinder Tammali; Ashish Saxena; Satish K Srivastava; Kota V Ramana
Journal:  Endocrinology       Date:  2010-03-22       Impact factor: 4.736

3.  Phosphorylation of pleckstrin increases proinflammatory cytokine secretion by mononuclear phagocytes in diabetes mellitus.

Authors:  Yong Ding; Alpdogan Kantarci; John A Badwey; Hatice Hasturk; Alan Malabanan; Thomas E Van Dyke
Journal:  J Immunol       Date:  2007-07-01       Impact factor: 5.422

Review 4.  Role of Takeda G protein‑coupled receptor 5 in microvascular endothelial cell dysfunction in diabetic retinopathy (Review).

Authors:  Miao Zhang; Zhenghao Dong; Wenkang Dong; Dongdong Zhou; Xiang Ren
Journal:  Exp Ther Med       Date:  2022-09-15       Impact factor: 2.751

5.  Effects of stimulation of soluble guanylate cyclase on diabetic nephropathy in diabetic eNOS knockout mice on top of angiotensin II receptor blockade.

Authors:  Ina M Ott; Markus L Alter; Karoline von Websky; Axel Kretschmer; Oleg Tsuprykov; Yuliya Sharkovska; Katharina Krause-Relle; Jens Raila; Andrea Henze; Johannes-Peter Stasch; Berthold Hocher
Journal:  PLoS One       Date:  2012-08-10       Impact factor: 3.240

6.  Effect of the G-308A polymorphism of the tumor necrosis factor (TNF)-alpha gene promoter site on plasma levels of TNF-alpha and C-reactive protein in smokers: a cross-sectional study.

Authors:  Marie-Louise Gander; Joachim E Fischer; Friedrich E Maly; Roland von Känel
Journal:  BMC Cardiovasc Disord       Date:  2004-10-14       Impact factor: 2.298

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.